Search This Blog

Wednesday, March 6, 2019

Allergan hit after rapastinel fails to meet primary endpoint in studies

In after-hours trading, shares are down about 5% to $131.05
https://thefly.com/landingPageNews.php?id=2875471

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.